Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 1819-1825

  Welsh, Liam ^a   Powell, Ceri ^a   Pratt, Brenda ^a   Harrington, Kevin ^a   Nutting, Chris ^a   Harmer, Clive ^a   Newbold, Kate ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR ABLATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84877713652     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1197     Document Type: Article

References (25)

1. Globocan 2008. Most frequent cancers: both sexes. http://globocan. iarc.fr/factsheets/populations/factsheet.asp?uno-900#BOTH. Accessed December 5, 2012.
2. Sawka AM, Brierley JD, Tsang, RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008:37:457-480.
3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
4. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265-271.
5. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651-659.
6. Rosário PW, Purisch S, Vasconcelos FP, Padrão EL, Rezende LL, Barroso AL. Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine. Nucl Med Commun. 2007;28:507-508.
7. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am. 1990; 19:741-760.
8. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
9. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235-1245.
10. Mallick U, Harmer C, Yap, B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012; 366:1674-1685.
11. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663-1673.
12. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96:1352-1359.
13. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118: 1131-1136; discussion 1136-1138.
14. Kukulska A, Krajewska J, Gawkowska-Suwiska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res. 2010;3:9.
15. MäenpääHO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One. 2008;3: e1885.
16. Cancer Research UK. Breast cancer incidence statistics. 2012. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/ #risk. Accessed December 5, 2012.
17. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 3-900051-07-0. http://www.R-project.org. Accessed December 5, 2012.
18. Gross A, Ziepert M, Scholz M. KM Win-a convenient tool for graphical presentation of results from Kaplan-Meier survival time analysis. PLoS One. 2012;7:e38960.
19. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28-38.
20. British Thyroid Association. Guidelines for the management of thyroid cancer. 2nd ed. London: Royal College of Physicians; 2007. http://www.british- thyroid-association.org/news/Docs/Thyroid-cancer-guidelines-2007.pdf. Accessed December 5, 2012.
21. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012;151:844-850.
22. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1277-1286.
23. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225-231.
24. Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol. 1992;168:337-343.
25. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 1997;75:734-739.